Literature DB >> 9039515

Altered follicle stimulating hormone isoforms in female galactosaemia patients.

L L Prestoz1, A S Couto, Y S Shin, K G Petry.   

Abstract

UNLABELLED: Many women affected with galactosaemia suffer from ovarian dysfunction and have elevated serum levels of follicle stimulating hormone (FSH). We have analysed FSH-glycoprotein isoforms from four galactosaemic and five healthy women. Besides the commonly found FSH species with a median isoelectric point (pI) of 4-5, the sera of the female galactosaemic patients contained qualitatively abnormal FSH isoforms with a pI close to neutral (6.4-7.0). The generally reduced galactosylation in patient samples was confirmed because sera of galactosaemic patients could incorporate 1.7 times more UDP-(14C)galactose than did healthy subjects.
CONCLUSION: Our data indicate that the terminal disaccharides of FSH (a glycoprotein), galactose and sialic acid were partially deficient in three galactosaemic female patients with no galactose-1-phosphate uridyl transferase (GALT) activity in red cells. However, from a female patient with a residual GALT activity (a mild form of galactosaemia), no distinctive deficiency was observed. This again suggest an importance of GALT in retaining a correct FSH structure. Therefore the abundance of neutral FSH isoforms, which was described to have a higher binding affinity to its receptor and no capacity to activate cyclic adenosine mono-phosphate (cAMP), may cause a hormonal dysfunction in classical galactosaemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039515     DOI: 10.1007/s004310050568

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

Review 1.  Innovative therapy for Classic Galactosemia - tale of two HTS.

Authors:  M Tang; S I Odejinmi; H Vankayalapati; K J Wierenga; K Lai
Journal:  Mol Genet Metab       Date:  2011-10-01       Impact factor: 4.797

2.  Komrower Lecture. Galactosaemia today: the enigma and the challenge.

Authors:  S Segal
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 3.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

4.  N- and O-linked glycosylation of total plasma glycoproteins in galactosemia.

Authors:  Ying Liu; Baoyun Xia; Tyler J Gleason; Uriel Castañeda; Miao He; Gerard T Berry; Judith L Fridovich-Keil
Journal:  Mol Genet Metab       Date:  2012-06-12       Impact factor: 4.797

Review 5.  Classical galactosaemia revisited.

Authors:  Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2006-07-11       Impact factor: 4.982

6.  Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia.

Authors:  Bijina Balakrishnan; Ding An; Vi Nguyen; Christine DeAntonis; Paolo G V Martini; Kent Lai
Journal:  Mol Ther       Date:  2019-09-19       Impact factor: 11.454

Review 7.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2009-12       Impact factor: 4.741

8.  Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Authors:  Ashwini Maratha; Hugh-Owen Colhoun; Ina Knerr; Karen P Coss; Peter Doran; Eileen P Treacy
Journal:  JIMD Rep       Date:  2016-08-09

9.  Pregnancy and delivery after stimulation with rFSH of a galatosemia patient suffering hypergonadotropic hypogonadism: case report.

Authors:  Yves J R Menezo; Maryse Lescaille; Bernard Nicollet; Edouard J Servy
Journal:  J Assist Reprod Genet       Date:  2004-03       Impact factor: 3.412

10.  Biomarkers of ovarian function in girls and women with classic galactosemia.

Authors:  Rebecca D Sanders; Jessica B Spencer; Michael P Epstein; Susan V Pollak; Pratibhasri A Vardhana; Joyce W Lustbader; Judith L Fridovich-Keil
Journal:  Fertil Steril       Date:  2008-08-05       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.